HPV-16 vaccine

BIOLOGICAL2 trials

Sponsors

University of Maryland, Baltimore, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Conditions

Anal Intraepithelial NeoplasiaHIVSquamous Cell Carcinoma of the Head and Neck

Phase 1

0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck

CompletedNCT00257738

University of Maryland, BaltimoreSquamous Cell Carcinoma of the Head and Neck

Start: 2005-11-30End: 2012-10-31Updated: 2019-10-17

Therapeutic HPV-16 Vaccination for the Treatment of Anal Dysplasia

CompletedNCT01923116

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Anal Intraepithelial Neoplasia, HIV

Start: 2013-08-31End: 2017-12-31Updated: 2018-03-15

Related Papers

A phase I dose escalation trial of MAGE-A3 and HPV-16 specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).

Journal of Clinical Oncology2014-05-204 citations